ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Houston, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Houston, TX, USA:

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (MoveS-it)

A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts:Part A - first in human ...

Active, not recruiting
Multiple Sclerosis (MS)
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: ANK-700

Phase 1

Anokion

Houston, Texas, United States and 14 other locations

of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Best Available Therapy (BAT)

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Houston, Texas, United States and 18 other locations

will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...

Active, not recruiting
Multiple Sclerosis (MS)
Drug: Ocrelizumab
Drug: rHuPH20

Phase 1

Roche
Roche

Houston, Texas, United States and 20 other locations

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Drug: Ocrelizumab

Phase 3

Roche
Roche

Houston, Texas, United States and 120 other locations

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Drug: Disease modifying treatment (DMT)
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Houston, Texas, United States and 33 other locations

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: Ofatumumab

Phase 3

Novartis
Novartis

Houston, Texas, United States and 122 other locations

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...

Active, not recruiting
Relapse Remitting Multiple Sclerosis
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Houston, Texas, United States and 35 other locations

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Houston, Texas, United States and 211 other locations

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Remibrutinib
Drug: Teriflunomide

Phase 3

Novartis
Novartis

Houston, Texas, United States and 229 other locations

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects w...

Enrolling
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: PIPE-307 Dose B

Phase 2

Contineum Therapeutics

Houston, Texas, United States of America and 24 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems